Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Jun 1;62(6):2060-2069.
doi: 10.1093/rheumatology/keac628.

Improving outcomes in scleroderma: recent progress of cell-based therapies

Dinesh Khanna  1 , Nancy Krieger  2 , Keith M Sullivan  3
Affiliations
Review

Improving outcomes in scleroderma: recent progress of cell-based therapies

Dinesh Khanna et al. Rheumatology (Oxford). .

Abstract

Scleroderma is a rare, potentially fatal, clinically heterogeneous, systemic autoimmune connective tissue disorder that is characterized by progressive fibrosis of the skin and visceral organs, vasculopathy and immune dysregulation. The more severe form of the disease, diffuse cutaneous scleroderma (dcSSc), has no cure and limited treatment options. Haematopoietic stem cell transplantation has emerged as a potentially disease-modifying treatment but faces challenges such as toxicity associated with fully myeloablative conditioning and recurrence of autoimmunity. Novel cell therapies-such as mesenchymal stem cells, chimeric antigen receptor-based therapy, tolerogenic dendritic cells and facilitating cells-that may restore self-tolerance with more favourable safety and tolerability profiles are being explored for the treatment of dcSSc and other autoimmune diseases. This narrative review examines these evolving cell therapies.

Keywords: cell transplantation; haematopoietic; immunotherapy; scleroderma and related disorders; skin; stem cell.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
The modified allogeneic HSCT FCR001. FCR001 is a proprietary blend of three cell types: (i) haematopoietic stem cells, progenitor cells used to rebuild the haematopoietic immune system of the recipient, (ii) facilitating cells, a mixed population of CD8+/TCR− cells that aid fast and efficient engraftment of donor HSCs to promote chimerism, and (iii) αβTCR+ T cells, a cell type that supports donor HSC engraftment but is also known to increase the risk of acute GvHD in the recipient. FCR001 utilizes an optimized number of αβTCR+ T cells in order to promote HSC engraftment while minimizing the risk of acute GvHD. GvHD: graft-vs-host disease; HSC: haematopoietic stem cell; HSCT: HSC transplant; TCR: T cell receptor
See this image and copyright information in PMC

References

    1. Sobolewski P, Maślińska M, Wieczorek M. et al. Systemic sclerosis – multidisciplinary disease: clinical features and treatment. Reumatologia 2019;57:221–33. - PMC - PubMed
    1. Denton CP, Khanna D.. Systemic sclerosis. Lancet 2017;390:1685–99. - PubMed
    1. Burbelo PD, Gordon SM, Waldman M. et al. Autoantibodies are present before the clinical diagnosis of systemic sclerosis. PLoS One 2019;14:e0214202. - PMC - PubMed
    1. van den Hoogen F, Khanna D, Fransen J. et al. 2013 classification criteria for systemic sclerosis: an American College of Rheumatology/European League against Rheumatism collaborative initiative. Arthritis Rheum 2013;65:2737–47. - PMC - PubMed
    1. Wu W, Jordan S, Graf N. et al.; EUSTAR Collaborators. Progressive skin fibrosis is associated with a decline in lung function and worse survival in patients with diffuse cutaneous systemic sclerosis in the European Scleroderma Trials and Research (EUSTAR) cohort. Ann Rheum Dis 2019;78:648–56. - PMC - PubMed

Publication types